Clinical Psychopharmacology · Paper A
Pharmacodynamic terms
Pharmacodynamics describes what a drug does to its target once bound. AffinityHow strongly a drug binds to its receptor.Read more → is how tightly a drug binds a receptor; potencyHow small a dose of a drug is needed to produce a given effect.Read more → is the dose needed for a given effect; efficacy is the maximal effect a drug can produce, no matter the dose. Clinically, efficacy is what actually determines how well a drug can work for a patient, e.g. a more potent antipsychotic is not necessarily a more effective one if both reach the same ceiling response.
A full agonistA drug or chemical that activates a receptor to produce an effect.Read more → (a drug that fully activates a receptor) achieves the receptor's maximal possible response. A partial agonistA drug that activates a receptor but produces a smaller effect than a full agonist, even at a high dose.Read more → binds the same site but cannot exceed a lower ceiling even at full occupancy, as with buprenorphine versus methadone at mu-opioid receptors. An antagonistA drug that blocks a receptor, stopping it from being activated.Read more → occupies the receptor without activating it, blocking agonist effects either competitively (surmountable by raising agonist concentration) or non-competitively (insurmountable). An inverse agonistA drug that binds a receptor and produces the opposite effect to what activating it normally causes.Read more → actively reduces baseline receptor activity, the opposite direction to an agonist. In practice, giving a competitive antagonist alongside a rising dose of the agonist it opposes, e.g. naloxone against a climbing opioid dose, lets the agonist eventually win out, unlike a non-competitive block, which cannot be overcome this way.
Every prescribing decision a doctor makes rests on pharmacodynamics (the study of what a drug does to the body once it reaches its target), as opposed to pharmacokinetics (what the body does to the drug: absorbing, distributing, breaking down, and excreting it). A fresh MBBS graduate hears words like , , and efficacy used almost interchangeably in casual conversation, but in pharmacology they mean precisely different things, and mixing them up leads to real prescribing errors. For example, imagine choosing a "more potent" drug over a genuinely "more effective" one because the two words sound similar; that mistake can leave a patient undertreated even though the prescription looks perfectly reasonable on paper.
Affinity (how tightly a drug binds its receptor) determines whether a drug engages its target at all. Potency (the dose needed to produce a given effect) tells you how much drug you need to get there. Efficacy (the maximal effect a drug can produce, no matter how high the dose goes) tells you the ceiling of what the drug can ever achieve. These three ideas answer three different questions: does it bind, how much do I need, and how far can it go, and none of them can substitute for either of the others.
The single most common error is treating "more potent" as if it meant "works better." It doesn't. Two drugs can have very different , needing very different doses for the same effect, while sharing identical efficacy, reaching exactly the same maximum benefit. A weak (low-potency) drug given at a higher dose can match a strong (high-potency) drug given at a lower dose, so long as both share the same efficacy ceiling. Clinically, efficacy is usually the more important variable, because a highly potent drug that plateaus at a low maximum effect may still undertreat a severe presentation: potency tells you the starting dose, efficacy tells you whether the drug was ever capable of solving the problem.
All of this traces back to receptor occupancy: a drug's clinical effect depends on how it engages its target receptor and what happens once it's bound. A full agonist (a drug that fully activates a receptor) can achieve the receptor's complete maximal response: high affinity plus full activation. A partial agonist activates the same receptor but, even at 100% occupancy, cannot exceed a lower ceiling than a full agonist, exactly as seen with buprenorphine compared with methadone at mu-opioid receptors: both bind the same site, but buprenorphine's maximum effect plateaus below methadone's. An occupies the receptor without activating it at all, simply blocking the effect of whatever agonist is trying to bind. An inverse agonist goes a step further, actively reducing receptor activity below its normal resting baseline, the opposite direction to what an agonist does. Understanding this occupancy-and-activation logic explains why affinity, , and efficacy can vary independently of each other.
Antagonism itself splits into two mechanisms worth knowing precisely. Competitive antagonism is surmountable: raising the concentration high enough can still push past the block, because both molecules compete reversibly for the same binding site: think of it as two people racing for the same parking spot, where enough determination (concentration) from one side can still win out. Non-competitive antagonism is insurmountable, because the binds a different, allosteric site or binds irreversibly, so no amount of extra agonist restores the full response: no matter how many extra cars show up, the spot has been welded shut. Consider a worked example: a patient on a low- antipsychotic (dopamine receptor competitive antagonist) shows only partial improvement in psychotic symptoms. Increasing the dose within the licensed range is reasonable if the drug's efficacy ceiling has not yet been reached, this is a potency problem, solvable by titration. But if the patient is already at the maximum licensed dose and still not responding, the problem is efficacy, not potency, and no further dose increase will ever exceed that drug's inherent ceiling.
Several pairs of pharmacodynamic terms are routinely confused. versus efficacy: affinity is about binding tightly, efficacy is about the size of the effect once bound: a drug can bind very tightly (high affinity) yet produce only a modest maximal effect (low efficacy), as with a . versus efficacy: potency is about the dose required, efficacy is about the ceiling reached: a low-potency drug can still be fully as effective as a high-potency one if you simply give more of it, provided their efficacy ceilings match. versus : an antagonist merely blocks an effect and leaves baseline activity unchanged if no agonist is present, while an inverse agonist actively pushes activity below baseline even with no agonist around. Competitive versus non-competitive antagonism: the discriminator is whether extra agonist can ever overcome the block (competitive, surmountable) or not (non-competitive, insurmountable).
There is no lab test for this; instead, the diagnosis is a prescribing diagnosis rather than a disease diagnosis: it is worked out through structured clinical reasoning about dose-response. When a patient fails to respond adequately to a standard dose, the clinician asks: has the drug actually been titrated to the top of its licensed range, and is there any sign the response is still climbing with each dose increase? If yes, this looks like a issue: the right target has been engaged, but not with enough dose yet. If the patient is already at the maximum licensed (and tolerated) dose with no further gain, or previous adequate trials of the same drug class have already failed, that is evidence of an efficacy ceiling, meaning no amount of extra dose of that particular drug will achieve the desired response. Reviewing prior medication trials, doses reached, and duration of each trial is the practical "test" pharmacodynamic reasoning depends on.
Pharmacodynamic reasoning underpins therapeutic drug monitoring and dose titration in everyday psychiatric practice, and it directly shapes what a clinician does next. Where a problem is suspected, first-line management is dose titration within the licensed range, guided by the BNF (British National Formulary) and, in psychiatry, the Maudsley Prescribing Guidelines, which translate affinity, potency, and efficacy data into practical starting doses, titration schedules, and maximum doses. Where an efficacy ceiling is suspected, the correct next step is usually to switch to a different drug (often from a different receptor-binding class entirely) rather than push the dose further, following NICE-aligned stepped-care principles for treatment-resistant presentations. Safety is a separate pharmacodynamic concept worth managing deliberately: the (the separation between the toxic dose and the effective dose) explains why benzodiazepines are considered safer in overdose than older barbiturates, despite both classes having broadly comparable (anxiety-reducing) potency at therapeutic doses: the danger lies not in how potent the drug is but in how close its toxic and effective doses sit together, and prescribers should always weigh therapeutic index alongside potency and efficacy when choosing between drugs.
Examiners love testing the buprenorphine-versus-methadone pair precisely because it separates candidates who understand partial agonism from those who don't: buprenorphine has higher for the mu-opioid receptor than methadone (it can even displace methadone from the receptor), yet it produces a lower maximal effect because it is only a partial agonist: high affinity does not mean high efficacy, and a question that describes a drug "outcompeting" another at the receptor is testing affinity, not . The second classic trap is the "just increase the dose" answer choice offered when the vignette actually describes a patient already at maximum licensed dose with no improvement: that is an efficacy ceiling, and the correct answer is to switch drugs, not push the dose higher.
tells you if a drug binds, tells you how much you need, and efficacy tells you the ceiling of what it can ever achieve, and confusing potency with efficacy is the single most common pharmacodynamic mistake in prescribing.